Mereo BioPharma Group plc Result of AGM (8157C)
20 June 2019 - 4:00PM
UK Regulatory
TIDMMPH
RNS Number : 8157C
Mereo BioPharma Group plc
20 June 2019
Mereo BioPharma Group plc
("Mereo" or the "Company" or the "Group")
Results of Annual General Meeting
London and Redwood City, Calif., June 20, 2019 - Mereo BioPharma
Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage
biopharmaceutical company focused on rare diseases, announces that
all resolutions proposed at the Annual General Meeting, held
yesterday, were duly passed. The Board is pleased that all the
resolutions received strong support from shareholders and reports
that Resolutions 1 to 6 passed as ordinary resolutions and
Resolution 7 was passed as a special resolution.
About Mereo
Mereo is a biopharmaceutical company focused on the development
and commercialization of innovative therapeutics that aim to
improve outcomes for patients with rare diseases. Mereo's strategy
is to selectively acquire product candidates for rare diseases that
have already received significant investment from pharmaceutical
and large biotechnology companies and that have substantial
preclinical, clinical and manufacturing data packages. Mereo's
existing portfolio consists of six clinical stage product
candidates.
-- Setrusumab for osteogenesis imperfecta (OI). In October 2018,
the Company announced completion of enrollment of 112 adult
patients in a Phase 2b dose ranging study with initial positive
6-month open label data announced in May 2019 and top-line 12-month
blinded dose ranging data expected in Q4 2019. A pediatric Phase 3
study design has also been approved by the EMA. Setrusumab has
orphan designation in the U.S. and the EU and has been accepted
into the PRIME and Adaptive Pathways in EU;
-- Alvelestat for alpha-1 antitrypsin deficiency (AATD). The Company has initiated a Phase 2 proof-of-concept clinical trial in patients with severe AATD in the United States and the EU and expects to report top-line data from this trial at or about the end of 2019;
-- Acumapimod for severe exacerbations of COPD. The Company
announced positive Phase 2 data in May 2018 and recently announced
the outline of the pivotal Phase 3 study including the primary and
key secondary endpoints following the successful end of Phase 2
Type B meeting with the FDA;
-- Leflutrozole for hypogonadotropic hypogonadism (HH). The
Company announced positive top-line Phase 2b data in March 2018 and
positive results from the Phase 2b safety extension study in
December 2018;
-- Navicixizumab has completed a Phase 1a single-agent clinical
trial in patients with advanced solid tumors and is currently in a
Phase 1b trial in combination with a standard paclitaxel regimen in
patients with platinum-resistant ovarian cancer. This study
recently completed enrolment; and
-- Etigilimab has completed a single-agent Phase 1a trial in
patients with advanced or metastatic solid tumors and the Phase 1b
combination study with nivolumab has fully enrolled and is
currently in the safety monitoring phase.
Further Enquiries
Mereo +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
Richard Jones, Chief Financial Officer
Cantor Fitzgerald Europe (Nominated Adviser
and Joint Broker to Mereo) +44 (0)20 7894 7000
Phil Davies
Will Goode
RBC Capital Markets (Joint Broker to Mereo) +44 (0)20 7653 4000
Rupert Walford
Jamil Miah
FTI Consulting (Public Relations Adviser to
Mereo)
Simon Conway +44 (0)20 3727 1000
Brett Pollard
Ciara Martin
Burns McClellan (US Public Relations Adviser +01 (0) 212 213
to Mereo) 0006
Lisa Burns
Steve Klass
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGCKCDDABKDOAD
(END) Dow Jones Newswires
June 20, 2019 02:00 ET (06:00 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024